Close Close
Sign In
Newsletters
Popular Financial Topics Discover relevant content from across the suite of ALM legal publications From the Industry More content from ThinkAdvisor and select sponsors Investment Advisor Issue Gallery Read digital editions of Investment Advisor Magazine Tax Facts Get clear, current, and reliable answers to pressing tax questions
Luminaries Awards
Podcast Center Video Center Webcasts Resource Center Events
About ThinkAdvisor Contact Us Advertise With Us Asset & Logo Licensing Sitemap Terms of Service Privacy Policy Copyright © 2024 ALM Global, LLC. All Rights Reserved.
ThinkAdvisor
Grail's cancer test has a $1,250 retail price. (Image: Galleri)

Life Health > Life Insurance > Permanent Life Insurance

Insurer to Offer Some a High-Tech Cancer Screening Test

By Allison Bell

X
Your article was successfully shared with the contacts you provided.

The Savings Bank Mutual Life Insurance Co. of Massachusetts has added an important benefit for some holders of its bank-owned life insurance: a chance to take Grail’s Galleri cancer screening blood test.

The test uses gene sequencing technology to detect traces of about 50 kinds of cancer, including ovarian and pancreatic cancer, at the earliest possible stages.

The current list price of the test is $949.

SBLI is offering access to the Galleri test through a pilot program that will be offered to some of the company’s BOLI customers.

SBLI wants to see how access to the test affects customers and will use the results of the pilot program to decide whether to make the test available to more customers, the company said.

Other life insurers that have experimented with offering the Galleri test include John Hancock and MassMutual.

Research: ”Liquid biopsy” tests are so new that researchers are still determining how to evaluate their impact.

In February, for example, Grail researchers published a paper on a simulation designed to show what testing outcomes might look like and to shape how cancer screening trials for the Galleri test might work.

Grail and its competitors are also having to persuade skeptics that offering patients access to a multi-cancer early detection test is helpful.

Grail representatives gave an oral presentation in April at the American Association for Cancer Research annual meeting on a test that will provide Galleri screening for 35,000 people across North America, to see how well the test works and what people do with the test results.

Credit: Galleri

Allison Bell

Think_Allison

NOT FOR REPRINT

© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.